Chondroitin and Glucosamine in the Management of Osteoarthritis: an Update

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2013 Aug 20

PMID 23955063

Citations 16

Authors

Yves Henrotin

Cecile Lambert

Affiliations

Soon will be listed here.

Abstract

The objective of osteoarthritis (OA) treatment is not only control of symptoms (i.e. reducing pain and improving function) but also to preserve joint structure and maintain quality of life. OA management remains challenging. Glucosamine and chondroitin are two compounds available for treatment of OA patients. Taken alone or in combination, they have a good safety profile and a variety of effects. In-vitro and in-vivo experiments have revealed that both compounds induced key intermediates in the OA pathophysiological process. Clinical trials, although providing conflicting and questionable results, report symptomatic and structure-modifying effects for both pharmaceutical-grade compounds. This review will discuss all these subjects and emphasize the importance of the quality of tested compounds for achieving high quality clinical trials.

Citing Articles

A Highly Active Chondroitin Sulfate Lyase ABC for Enzymatic Depolymerization of Chondroitin Sulfate.

Fan X, Huang J, Ling X, Wei W, Su W, Zhang Y Polymers (Basel). 2022; 14(9).

PMID: 35566938 PMC: 9100776. DOI: 10.3390/polym14091770.

Efficient production of D-glucosamine by diacetylchitobiose deacetylase catalyzed deacetylation of N-acetyl-D-glucosamine.

Wang L, Hu M, Tao Y Biotechnol Lett. 2022; 44(3):473-483.

PMID: 35072843 DOI: 10.1007/s10529-022-03225-2.

Emerging microfluidics-enabled platforms for osteoarthritis management: from benchtop to bedside.

Zou Z, Luo X, Chen Z, Zhang Y, Wen C Theranostics. 2022; 12(2):891-909.

PMID: 34976219 PMC: 8692897. DOI: 10.7150/thno.62685.

CS-semi5 Inhibits NF-κB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis.

Li X, Tang X, Wang Y, Chai C, Zhao Z, Zhang H Front Pharmacol. 2021; 12:655101.

PMID: 34305585 PMC: 8298759. DOI: 10.3389/fphar.2021.655101.

The P2X7 Receptor in Osteoarthritis.

Li Z, Huang Z, Bai L Front Cell Dev Biol. 2021; 9:628330.

PMID: 33644066 PMC: 7905059. DOI: 10.3389/fcell.2021.628330.

References

Katta J, Jin Z, Ingham E, Fisher J . Chondroitin sulphate: an effective joint lubricant?. Osteoarthritis Cartilage. 2009; 17(8):1001-8. DOI: 10.1016/j.joca.2009.02.010. View

Lin Y, Liang Y, Sheu M, Lin Y, Hsieh M, Chen T . Chondroprotective effects of glucosamine involving the p38 MAPK and Akt signaling pathways. Rheumatol Int. 2008; 28(10):1009-16. DOI: 10.1007/s00296-008-0561-4. View

Holzmann J, Brandl N, Zemann A, Schabus R, Marlovits S, Cowburn R . Assorted effects of TGFbeta and chondroitinsulfate on p38 and ERK1/2 activation levels in human articular chondrocytes stimulated with LPS. Osteoarthritis Cartilage. 2006; 14(6):519-25. DOI: 10.1016/j.joca.2005.12.005. View

Ivanovska N, Dimitrova P . Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther. 2011; 13(2):R44. PMC: 3132029. DOI: 10.1186/ar3283. View

Chan P, Caron J, Orth M . Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res. 2005; 66(11):1870-6. DOI: 10.2460/ajvr.2005.66.1870. View

Hochberg M, Zhan M, Langenberg P . The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate . Curr Med Res Opin. 2008; 24(11):3029-35. DOI: 10.1185/03007990802434932. View

Uebelhart D, Malaise M, Marcolongo R, De Vathaire F, DeVathaire F, Piperno M . Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004; 12(4):269-76. DOI: 10.1016/j.joca.2004.01.004. View

Kapoor M, Mineau F, Fahmi H, Pelletier J, Martel-Pelletier J . Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2011; 39(3):635-44. DOI: 10.3899/jrheum.110621. View

Calamia V, Lourido L, Fernandez-Puente P, Mateos J, Rocha B, Montell E . Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther. 2012; 14(5):R202. PMC: 3580514. DOI: 10.1186/ar4040. View

10.

Henrotin Y, Chevalier X, Herrero-Beaumont G, McAlindon T, Mobasheri A, Pavelka K . Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Res Notes. 2013; 6:115. PMC: 3629992. DOI: 10.1186/1756-0500-6-115. View

11.

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

12.

Baccarin R, Machado T, Lopes-Moraes A, Vieira F, Michelacci Y . Urinary glycosaminoglycans in horse osteoarthritis. Effects of chondroitin sulfate and glucosamine. Res Vet Sci. 2011; 93(1):88-96. DOI: 10.1016/j.rvsc.2011.08.009. View

13.

Ali A, Lewis S, Badgley H, Allaben W, Leakey J . Oral glucosamine increases expression of transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: implications for human efficacy and toxicity. Arch Biochem Biophys. 2011; 510(1):11-8. DOI: 10.1016/j.abb.2011.03.014. View

14.

Aghazadeh-Habashi A, Jamali F . The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci. 2011; 14(2):264-73. DOI: 10.18433/j3xg6f. View

15.

Kahan A, Uebelhart D, De Vathaire F, Delmas P, Reginster J . Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009; 60(2):524-33. DOI: 10.1002/art.24255. View

16.

Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4):476-99. DOI: 10.1016/j.joca.2010.01.013. View

17.

Michel B, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P . Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005; 52(3):779-86. DOI: 10.1002/art.20867. View

18.

Campo G, Avenoso A, Campo S, Ferlazzo A, Calatroni A . Chondroitin sulphate: antioxidant properties and beneficial effects. Mini Rev Med Chem. 2006; 6(12):1311-20. DOI: 10.2174/138955706778993012. View

19.

Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004; 64(5):669-81. PMC: 1755499. DOI: 10.1136/ard.2004.028886. View

20.

Wen Z, Tang C, Chang Y, Huang S, Hsieh S, Lee C . Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthritis Cartilage. 2010; 18(9):1192-202. DOI: 10.1016/j.joca.2010.05.012. View